Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224146 · ClinicalTrials.gov registry record · Phase 4
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
A Phase 4 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,878
- Enrollment target
NCT00224146: Completed Phase 4 study, sponsored by Watson Pharmaceuticals.
NCT00224146 is a Phase 4 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 2,878 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (456% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00224146, a Phase 4 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,878 participants
- Enrollment target
Study Summary
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
Interventions
- DRUG oxybutynin transdermal delivery system (Oxytrol(r))
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,878 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
What the finished NCT00224146 record still lists
NCT00224146 is an interventional study that assigns participants to a tested intervention. Its 2,878 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (456% higher).
The record links to 0 conditions, and to 1 intervention - of which oxybutynin transdermal delivery system (Oxytrol(r)) is the first listed.
NCT00224146 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00224146 about?
NCT00224146 is a clinical study titled "Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder". This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
What is the current status of trial NCT00224146?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,878 participants. The study started on 2004-05. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00224146?
The interventions under investigation include: oxybutynin transdermal delivery system (Oxytrol(r)) (DRUG).
Who is sponsoring clinical trial NCT00224146?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00224146's enrollment target sits among peer trials
2,878 25th of 2000 higher than 1,976 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT06273436 · 2,894 participants · NA
Healing, Equity, Advocacy and Respect for Mamas
- NCT05564377 · 2,900 participants · Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia